{"id":16960,"date":"2023-07-04T13:05:17","date_gmt":"2023-07-04T11:05:17","guid":{"rendered":"https:\/\/www.hematostat.net\/?p=16960"},"modified":"2024-12-11T22:03:09","modified_gmt":"2024-12-11T21:03:09","slug":"benefice-a-long-terme-des-car-t-dans-les-lymphomes-b-diffus-a-grandes-cellules-dlbcl","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/benefice-a-long-terme-des-car-t-dans-les-lymphomes-b-diffus-a-grandes-cellules-dlbcl\/","title":{"rendered":"B\u00e9n\u00e9fice \u00e0 long terme des CAR T dans les lymphomes B diffus \u00e0 grandes cellules (DLBCL)"},"content":{"rendered":"

R\u00e9f. : HematoStat.net ; 4 (2) : R80<\/p>\n

<\/em>Neelapu SS, Jacobson CA, Ghobadi A, et al. <\/em>Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023 11;141(19):2307-2315.<\/em><\/a><\/em><\/p>\n

R\u00e9sum\u00e9 de l\u2019article<\/strong><\/p>\n

Cette \u00e9tude am\u00e9ricaine rapporte le suivi \u00e0 5 ans des patients porteurs de DLBCL en situation de rechute\/r\u00e9fractaire \u00e0 un traitement de premi\u00e8re ligne, trait\u00e9s par axi-cel (CAR T de seconde g\u00e9n\u00e9ration anti-CD19) dans l\u2019essai de phase 2 ZUMA-I. Avec un suivi m\u00e9dian de 63 mois, le taux de r\u00e9ponse persistante \u00e9tait de 31 %, et les survies globales et sans progression \u00e0 5 ans de 43 % et 51 % respectivement.<\/p>\n

Dans nos pratiques<\/strong><\/p>\n

Ces donn\u00e9es importantes rapportent les premi\u00e8res estimations de survie \u00e0 long terme des patients DLBCL trait\u00e9s par CAR T, qui a donc permis des r\u00e9missions persistantes \u00e0 5 ans chez 1\/3 des patients. Il sera int\u00e9ressant de voir si ces r\u00e9sultats sont transposables en vie r\u00e9elle.<\/p>\n

Le regard du biostatisticien<\/strong><\/p>\n

Cette \u00e9tude permet de visualiser les perspectives \u00e0 moyen et long terme de cette phase 2, dont les suivis m\u00e9dians en termes de EFS, PFS et TTP n\u2019\u00e9taient que de 6 mois environ, contre 25 mois pour la survie globale. Cela dit, les patients survivants apr\u00e8s 6 mois voient leurs probabilit\u00e9s baisser que faiblement, un point encourageant. Dommage que les auteurs n\u2019aient pas effectu\u00e9s d\u2019analyses univari\u00e9s pour observer quels \u00e9taient param\u00e8tres peuvent potentiellement jouer sur les diff\u00e9rents endpoints<\/em>.<\/p>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":16961,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[36],"tags":[],"ppma_author":[459],"class_list":["post-16960","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-revue-de-presse","author-lin-pierre-zhao"],"aioseo_notices":[],"authors":[{"term_id":459,"user_id":0,"is_guest":1,"slug":"lin-pierre-zhao","display_name":"Lin-Pierre ZHAO","avatar_url":{"url":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2023\/06\/Capture-decran-2023-03-29-a-12.52.50-1.png","url2x":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2023\/06\/Capture-decran-2023-03-29-a-12.52.50-1.png"},"first_name":"","last_name":"","user_url":"","description":"H\u00e9matologue.
\r\nChef de clinique assistant
\r\nLiens d'int\u00e9r\u00eats au 06\/03\/2024 : <\/strong>l'auteur d\u00e9clare ne pas avoir de liens d'int\u00e9r\u00eats.
\r\nLiens d'int\u00e9r\u00eats au 01\/01\/2024 : <\/strong>l'auteur d\u00e9clare ne pas avoir de liens d'int\u00e9r\u00eats.
\r\nCorrespondance : <\/strong>Service H\u00e9matologie S\u00e9niors - Tr\u00e8fle 4 | H\u00f4pital Saint-Louis | Universit\u00e9 Paris Cit\u00e9\r\nInserm U1160 | Institut de Recherche Saint-Louis\r\n1 avenue Claude Vellefaux, 75010 Paris.
"}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16960","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=16960"}],"version-history":[{"count":4,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16960\/revisions"}],"predecessor-version":[{"id":18304,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16960\/revisions\/18304"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media\/16961"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=16960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=16960"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=16960"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=16960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}